» Articles » PMID: 32624424

Prognostic Significance of Serum Lactate Dehydrogenase in Patients Undergoing Radical Cystectomy for Bladder Cancer

Overview
Journal Urol Oncol
Publisher Elsevier
Date 2020 Jul 7
PMID 32624424
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To investigate the prognostic significance of preoperative serum lactate dehydrogenase (LDH) in patients undergoing radical cystectomy for bladder cancer (BCa).

Patients And Methods: A cohort of 263 patients undergoing open or laparoscopic radical cystectomy between 2011 and 2016 was studied. Baseline characteristics, hematological variables, follow-up data were collected. Kaplan-Meier curves and Cox proportional hazard regression model were applied to assess the relationship between LDH and overall survival (OS), cancer-specific survival (CSS), and disease-free survival (DFS).

Results: After a median 34.2 (22.9-45.8) months follow-up, all-cause death, cancer-specific death, and disease recurrence occurred in 66 patients, 50 patients, and 91 patients. The elevation of serum LDH was associated with several unfavorable parameters, including advanced age, continent cutaneous urinary diversion, increased neutrophil-to-lymphocyte ratio, decreased lymphocyte-to-monocyte ratio. Patients with a higher serum LDH (> 220 U/L) had a worse OS (P < 0.001), CSS (P < 0.001) and DFS (P < 0.001). Multivariate Cox analysis suggested that elevated LDH was an independent predictor for OS (hazard ratio [HR]: 3.113, 95% confidence interval [CI]: 1.524-6.358; P = 0.002), CSS (HR: 4.564, 95% CI: 2.008-10.373; P < 0.001), DFS (HR: 2.051, 95% CI: 1.125-3.739; P = 0.019). Medical history of diabetes, high pT stage, and positive lymph node also were adverse predictors for oncological outcomes of BCa patients in multivariate analysis.

Conclusions: Preoperative serum LDH is an independent prognostic biomarker for OS, CSS, and DFS in patients undergoing radical cystectomy for BCa, which can be incorporated into prognostic models.

Citing Articles

Novel Preoperative Immune Prognostic Index for Predicting Outcomes in Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma.

Shibata K, Iwatani K, Imai Y, Yoshihara K, Miyajima K, Fukuokaya W In Vivo. 2025; 39(2):824-833.

PMID: 40010955 PMC: 11884453. DOI: 10.21873/invivo.13885.


Pretreatment PLR Is Preferable to NLR and LMR as a Predictor in Locally Advanced and Metastatic Bladder Cancer.

Karan C, Yaren A, Demirel B, Dogan T, Ozdemir M, Demiray A Cancer Diagn Progn. 2023; 3(6):706-715.

PMID: 37927800 PMC: 10619568. DOI: 10.21873/cdp.10275.


Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma.

Alt M, Stecca C, Lin Y, Kazeem G, Goluboff E, Sridhar S BMC Cancer. 2023; 23(1):919.

PMID: 37773115 PMC: 10540375. DOI: 10.1186/s12885-023-11380-6.


Up-regulated serum lactate dehydrogenase could become a poor prognostic marker in patients with bladder cancer by an evidence-based analysis of 2,182 patients.

Wei X, Chai Y, Li Z, Che X, Zhang Y, Zhou Z Front Oncol. 2023; 13:1233620.

PMID: 37601656 PMC: 10435851. DOI: 10.3389/fonc.2023.1233620.


Blood-Based Biomarkers as Prognostic Factors of Recurrent Disease after Radical Cystectomy: A Systematic Review and Meta-Analysis.

Ofner H, Laukhtina E, Hassler M, Shariat S Int J Mol Sci. 2023; 24(6).

PMID: 36982918 PMC: 10056816. DOI: 10.3390/ijms24065846.